Latest News & Updates

Breaking News

  • 23 minutes ago

  • Vaibhavi M.

Tonix Pharmaceuticals Wins FDA IND Clearance To Advance TNX-102 SL For Phase 2 HORIZON Study, Targeting Unmet Needs In Major Depressive Disorder
Breaking News
Biogen And Dayra Therapeutics Launch Collaboration To Develop Oral Macrocyclic Peptides For Immunology; $50M Agreement Strengthens Biogen’s Immunology Pipeline

Vaibhavi M.

Other trending news you may like to read

Tonix Pharmaceuticals Wins FDA IND Clearance To Advance TNX-102 SL For Phase 2 HORIZON Study, Targeting Unmet Needs In Major Depressive Disorder

Tonix’s TNX-102 SL receives FDA IND clearance for Phase 2 testing in major depressive disorder, advancing a novel sleep-targeted approach to treating MDD.

Vaibhavi M.

Pharma Now

Biogen And Dayra Therapeutics Launch Collaboration To Develop Oral Macrocyclic Peptides For Immunology; $50M Agreement Strengthens Biogen’s Immunology Pipeline

Biogen and Dayra Therapeutics partner to develop oral macrocyclic peptides for immunology, expanding Biogen’s pipeline with next-generation therapeutic candidates.

Vaibhavi M.

Pharma Now

FDA Type B Meeting Supports Development Path For Plus Therapeutics’ Targeted Radiotherapy REYOBIQ In CNS Cancers

Plus Therapeutics completes FDA Type B meeting, advancing REYOBIQ toward a pivotal trial for leptomeningeal metastases, a rare and aggressive CNS cancer complication.

Vaibhavi M.

Pharma Now

European Commission Approves Bristol Myers Squibb’s Breyanzi For Relapsed Or Refractory Mantle Cell Lymphoma

EU approves BMS’s Breyanzi for relapsed or refractory mantle cell lymphoma after BTK inhibitor therapy, offering a durable CAR-T option for hard-to-treat patients.

Vaibhavi M.

Pharma Now